François Xavier Mahon
- Hematology top 1%
- Genetics top 1%
- Rheumatology top 2%
- Molecular Biology
- Oncology
- Co-authors
- Junia V. MeloJohn M. GoldmanJosy ReiffersMichael W. DeiningerJ. ChabrolBeate SchultheisMarie ParrensPierre Dubus
- Topics
- Chronic Myeloid Leukemia Treatments (22 papers)Chronic Lymphocytic Leukemia Research (17 papers)Eosinophilic Disorders and Syndromes (10 papers)
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- FranceUnited KingdomJapan
In The Last Decade
François Xavier Mahon
23 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Hematology 977
- Genetics 774
- Rheumatology 515
- Molecular Biology 283
- Oncology 189
Countries citing papers authored by François Xavier Mahon
This map shows the geographic impact of François Xavier Mahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Xavier Mahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Xavier Mahon more than expected).
Fields of papers citing papers by François Xavier Mahon
This network shows the impact of papers produced by François Xavier Mahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Xavier Mahon. The network helps show where François Xavier Mahon may publish in the future.
Co-authorship network of co-authors of François Xavier Mahon
This figure shows the co-authorship network connecting the top 25 collaborators of François Xavier Mahon. A scholar is included among the top collaborators of François Xavier Mahon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Xavier Mahon. François Xavier Mahon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 12 | |
| 3 | 10 | |
| 4 | 40 | |
| 5 | 17 | |
| 6 | 21 | |
| 7 | 39 | |
| 8 | 1 | |
| 9 | 11 | |
| 10 | 0 | |
| 11 | 37 | |
| 12 | 96 | |
| 13 | 4 | |
| 14 | 13 | |
| 15 | Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistancebreakdown → | 616 |
| 16 | 53 | |
| 17 | 154 | |
| 18 | 2 | |
| 19 | 2 | |
| 20 | 58 |
About François Xavier Mahon
François Xavier Mahon is a scholar working on Hematology, Genetics and Rheumatology, having authored 26 papers that have together received 1.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Eosinophilic Disorders and Syndromes (10 papers). The work is most often cited by research in Hematology (977 citations), Genetics (774 citations) and Rheumatology (515 citations). François Xavier Mahon has collaborated with scholars based in France, United Kingdom and Japan. Frequent co-authors include Junia V. Melo, John M. Goldman, Josy Reiffers, Michael W. Deininger, J. Chabrol, Beate Schultheis, Josy Reiffers, Marie Parrens, Pierre Dubus and Antoine de Mascarel. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.